Some people considering Wegovy want an alternative because they prefer tablets, have limited pharmacy access, face an insurance exclusion or want to understand other FDA-approved medicines for weight management. The right comparison begins with the labeled indication and individual clinical eligibility, not the shortest path to a checkout button. Wegovy contains semaglutide, but alternative medicines can contain tirzepatide, liraglutide, or different non-incretin ingredients.
Zepbound, Foundayo, Saxenda, orlistat, Qsymia, Contrave and phentermine do not form one interchangeable product family. Their routes, approved age groups, indications, treatment duration, safety warnings and prescribing conditions differ. For example, phentermine is generally associated with short-term use, whereas several other medications have approved chronic weight-management contexts; OTC Alli is also not equivalent to prescription Xenical by dose and labeling.
This hub helps identify a comparison worth discussing with a licensed clinician and connects to product-specific research and legitimate purchase routes. Diabetes-focused treatment alternatives belong to the Ozempic alternatives guide; buying Wegovy itself belongs to the Wegovy prescription and pharmacy guide.
A preference for tablets, difficulty accessing injections, a plan’s coverage limitation, a specific contraindication or an inadequate response are distinct questions. Patient age, indication, comorbidities and current medications all matter, and the FDA-approved product label is a better starting point than advertising claims of a “stronger” or “cheaper” equivalent.
This guide does not provide individualized eligibility screening or switching doses. A clinician must weigh product-specific evidence and risks.
The matrix separates class and route before financial considerations. Product availability and coverage are dynamic, and a drug’s inclusion here does not mean it suits every person considering Wegovy.
Individual head-to-head pages own the deeper evidence; this hub makes it clear what is being compared.
| Medicine | Product category | Buyer-relevant difference | Detailed path |
|---|---|---|---|
| Zepbound (tirzepatide) | Injectable dual GIP/GLP-1 agonist | Distinct molecule and approved product | Compare products |
| Foundayo (orforglipron) | Oral small-molecule GLP-1 agonist | Different oral molecule and FDA label | Compare oral products |
| Saxenda (liraglutide) | Injectable GLP-1 agonist | Daily injection versus Wegovy formats | Compare brands |
| Orlistat / Alli / Xenical | Gastrointestinal lipase inhibitor | Non-GLP-1 route; OTC versus Rx products | Compare mechanisms |
| Qsymia | Phentermine/topiramate extended-release | Distinct oral combination medicine | Compare options |
| Contrave | Naltrexone/bupropion combination | Distinct oral combination medicine | Compare options |
| Phentermine | Sympathomimetic appetite suppressant | Generally short-term treatment context | Compare roles |
Zepbound contains tirzepatide rather than semaglutide, acts at GIP and GLP-1 receptors and has its own labeled indications, warnings and injection product formats. Study outcomes should be compared only using relevant populations, doses, endpoints and direct trial evidence when available.
Read Wegovy versus Zepbound clinical/product comparison for evidence and how to obtain Zepbound legally for the prescription and pharmacy steps. The pricing comparison lives separately.
FDA approved Foundayo (orforglipron) in April 2026 for an indicated weight-management population. It is a different active ingredient from oral Wegovy, even though both can be presented as oral GLP-1 treatments. Their labeling, administration instructions and safety evidence must not be equated just because both are pills.
The focused clinical and purchasing comparison is Wegovy pill versus Foundayo, while Foundayo access explains the product-specific prescription route.
Saxenda contains liraglutide with a different injection schedule from weekly Wegovy. Generic liraglutide authorization relates to specific reference products and strengths; it should not be confused with generic semaglutide or assumed automatically equivalent to Saxenda for every case.
See Wegovy versus Saxenda and Saxenda prescription access. Clinical suitability and product labeling govern changes, not the presence of a generic ingredient name.
Orlistat limits fat absorption in the gastrointestinal tract and is not a GLP-1 therapy. Alli is a lower-strength OTC product and Xenical is a prescription product, with different labeling and buyer requirements. Both require consideration of the specific drug’s safety and use instructions.
The comparison Wegovy versus orlistat covers the mechanism tradeoff. For legal supply distinctions use Alli purchasing guide or Xenical purchasing guide.
Qsymia and Contrave have different ingredient combinations, contraindications, safety precautions and product programs. Choosing an oral medicine is not merely a preference for a different delivery route: the clinical risk and evidence profile may be substantially different from semaglutide.
Use Wegovy versus Qsymia and Wegovy versus Contrave to distinguish them. Access-specific steps belong on their respective Buy pages.
Phentermine is an older sympathomimetic medication associated with a short-term treatment indication. It should not be presented as a drop-in long-term equivalent to a product with chronic weight-management labeling. Controlled-substance rules and prescribing considerations can also apply.
See the Wegovy and phentermine comparison; the legal pharmacy and prescription guide is separate from clinical suitability.
For a person seeking to avoid weekly injections, FDA-approved Wegovy tablets may be relevant to the clinical conversation before considering an entirely different ingredient. Wegovy HD is a separate high-dose injection for certain adults, not a substitute that consumers should select to increase results.
The Wegovy pill-versus-pen guide examines route differences and the Wegovy HD page clarifies the separate approved presentation.
Coverage and manufacturer programs are linked to specific branded presentations, insurer formularies and eligibility rules. A product may be clinically indicated but excluded from a plan, or covered only after documentation. Do not compare costs using an assumed interchangeable milligram dose.
See Wegovy coverage rules and Wegovy versus Zepbound payment options for distinct financial tasks.
Once a clinician has selected a medicine, determine whether it requires a prescription, the precise product and strength, the licensed pharmacy, payer or self-pay terms, and appropriate follow-up. OTC access to one orlistat product does not waive prescription requirements for unrelated options.
Use the pharmacy verification checklist for an unfamiliar U.S. seller. Avoid overseas or compounded offers claiming to be FDA-approved generic Wegovy.
This independent guide explains product and purchasing questions but is not a pharmacy, prescriber, insurer, product-authentication laboratory or real-time inventory service. Some outbound commercial links elsewhere on this website may be affiliate or sponsored referrals, and the site may receive compensation when readers use them. Such relationships are disclosed alongside the relevant outbound link; compensation does not validate a seller or guarantee a prescription. Regulatory information was checked against FDA and other named official guidance on October 18, 2026; verify current requirements before acting.
Product categories and access distinctions were reviewed against U.S. FDA labels and the April 2026 Foundayo announcement on October 18, 2026. No treatment is designated “best,” and inclusion in this directory does not constitute a clinical recommendation or a paid ranking.
Options may include Zepbound, Foundayo, Saxenda and non-GLP-1 products such as orlistat, Qsymia or Contrave, depending on the patient and the product’s label.
No. Zepbound contains tirzepatide, while Wegovy contains semaglutide. They are different medicines.
No. Foundayo contains orforglipron and Wegovy tablets contain semaglutide. Both have their own FDA-approved labeling.
Alli is an OTC orlistat product at its labeled strength, whereas Xenical is a separate prescription orlistat product.
No. Phentermine has a generally short-term indicated use and different safety and prescribing considerations.
No. Different active ingredients, schedules and products require clinician-directed evaluation and instructions.
There is no universal answer. Costs depend on exact product, payment route, location and current terms, which should be verified rather than guessed.
No. Orlistat, phentermine, Qsymia and Contrave do not work by the same mechanism as semaglutide.
No. Approval is for defined uses and populations. A licensed clinician must assess personal risks, contraindications and treatment goals.